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Abstract
Background: The aim of the study was to evaluate the acute and continuous (up to 14 days of
treatment) effect of growth hormone (GH) on blood pressure (BP) regulation and to investigate
the interplay between GH, nitric oxide (NO) and BP.
In un-supplemented and GH supplemented hypophysectomized (Hx) male rats as well as intact rats,
continuous resting mean arterial blood pressure (MAP) was measured using telemetry.
Baroreceptor activity and the influences of NO on BP control were assessed during telemetric
measurement. Furthermore, basal plasma and urine nitrate levels and aortic endothelial nitric oxide
synthase (eNOS) expression were analysed. Endothelial function as well as vascular structure in the
hindquarter vascular bed was estimated using an in vivo constant-flow preparation.
Results: Hypophysectomy was associated with decreased MAP (Hx: 83 ± 3 vs Intact: 98 ± 6
mmHg, p < 0.05) and heart rate (HR) (Hx: 291 ± 4 vs Intact: 351 ± 7 beat/min, p < 0.05). Endothelial
dysfunction and reduced vasculature mass in the hindquarter vascular bed was found in Hx rats.
GH substitution caused a further transient decrease in MAP and a transient increase in HR (14%
and 16% respectively, p < 0.05). The reduction in MAP appeared to be NO dependent. Aortic
eNOS expression was unchanged. GH substitution resulted in an impaired baroreceptor function.
Two weeks of GH treatment did not normalise the BP, vascular structure and the endothelial
function in the resistance vessels.
Conclusion: GH substitution seems to have a short lasting effect on lowering blood pressure via
activation of the NO-system. An interaction between GH, NO-system and BP regulation can be
demonstrated.
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Background
Adult hypopituitarism and untreated growth hormone
(GH) deficiency (GHD) is associated with endothelial
dysfunction [1], decreased systemic formation of nitric
oxide (NO) [2] and increased risk for cardiovascular mor-
bidity and mortality [3] as compared to the normal popu-
lation [4]. There are disparate reports on the effect on
blood pressure (BP) in this condition; different studies
have found normotension, hypotension or hypertension
in GHD-patients (for review see [5]). Growth hormone
replacement has been shown to reverse many of the
adverse cardiovascular risk factors associated with GHD,
including decreased systolic and diastolic BP, decreased
vascular resistance [6], increased cardiac output (CO),
increased heart rate (HR) [2,6], improved endothelial
function [1,7] and increased NO formation [2].
Hypophysectomized (Hx) rats express decreased systolic
BP and mean arterial blood pressure (MAP), CO and HR
compared with intact rats [8,9]. As in human adult GHD,
these rats show endothelial dysfunction and impaired vas-
cular reactivity [10,11], while aortic endothelial nitric
oxide synthase (eNOS) expression is not affected [12].
Furthermore, these rats also display decreased heart
weights [12,13], and reduced vasculature mass in the
muscle vascular bed suggesting an hypotropic remodel-
ling of the cardiovascular system [13]. One week of GH
substitution in Hx rats does not result in a change in systo-
lic BP measured by the tail-cuff technique, whereas HR,
heart weight and aortic eNOS expression are increased
[12]. The resistance vessels (mesenteric artery) still dem-
onstrate endothelial dysfunction [10]. Previous studies on
BP regulation in Hx rats [10,12,13] have used less precise
techniques to measure BP i.e. tail-cuff technique and
therefore showed imprecise GH effect on acute and con-
tinuous BP regulation.
In the present study we aimed to investigate the acute and
continuous (up to 14 days of treatment) effect of growth
hormone substitution on blood pressure regulation. In
order to measure the true, unstressed BP, we used a telem-
etry technique with implantable transmitters. We were
Mean arterial blood pressure (MAP) in hypophysectomized (Hx, solid line), growth hormone supplemented Hx (GH, solid  squares) and in intact rats (solid triangles) Figure 1
Mean arterial blood pressure (MAP) in hypophysectomized (Hx, solid line), growth hormone supplemented Hx (GH, solid 
squares) and in intact rats (solid triangles). The first two days (-4 to -2) represent non-supplemented basal measurements of 
MAP in all groups. At day -2, all Hx rats received thyroxine and glucocorticoid [T4+GC] treatment with mini-osmotic pumps, 
whereas the intact rats underwent sham operation. At day zero, the onset of GH treatment (mini-osmotic pumps implanta-
tion) was performed in the GH animals, whereas both intact and Hx animals underwent sham operation. * indicate p<0.05 
between pre- and post-GH treatment in GH group.
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also interested in investigating the interplay between GH,
NO and BP. In order to do this we used a specific NOS
blocker and measured the aortic eNOS expression, basal
plasma and urine nitrate levels. In addition, baroreceptor
activity was examined both early and late after onset of
GH treatment. At the end of the study, endothelial func-
tion and the vascular structural properties in the hind-
quarter were studied using an in vivo constant-flow
preparation.
Results
Growth hormone causes a transient decrease in mean 
arterial blood pressure and a transient increase in heart 
rate, Fig 1 and 2
Hypophysectomy per se, caused a 17% decrease in MAP
and HR before onset of hormonal treatment (MAP; Intact:
98 ± 6, Hx: 83 ± 3, GH: 81 ± 5, p < 0.05 Intact vs GH or
Hx, Fig 1, HR; Intact: 351 ± 7, Hx: 291 ± 4, GH: 295 ± 7, p
< 0.05 Intact vs GH or Hx, Fig 2). Neither MAP nor HR
changed when the Hx rats were treated with [T4+GC] com-
pared with pre-treatment levels or with intact rats (day -2,
Fig 1 and 2). Growth hormone caused an immediate drop
in MAP by approx 14% (to 70 ± 4 mmHg, p < 0.05 vs Hx,
Fig 1) with a concomitant increase in HR by approx. 16%
(to 351 ± 6 beat/min, p < 0.05 vs Hx, Fig 2). After 14 days
of GH therapy, the MAP returned to pre-treatment levels
(day 14 = 81 ± 4 mmHg, Fig 1), indicating that GH had a
transient effect on BP regulation. Similarly, HR returned
to pre-treatment levels (pre-treatment = 319 ± 7 vs day 14
= 319 ± 8 beat/min, Fig 2). Mean arterial pressure was
unchanged in both Hx and intact rats during the treat-
ment period (Hx: 81 ± 3 to 83 ± 6 mmHg, Intact: 98 ± 6
to 95 ± 6 mmHg). In addition, no change in HR was
detected in Hx and intact rats during the treatment period
Heart rate (HR) in hypophysectomized (Hx, solid line), growth hormone supplemented Hx (GH, solid squares) and in intact  rats (solid triangles). Figure 2
Heart rate (HR) in hypophysectomized (Hx, solid line), growth hormone supplemented Hx (GH, solid squares) and in intact 
rats (solid triangles). The first two days (-4 to -2) represent non-supplemented basal measurements of HR in all groups. At day 
-2, all Hx rats received thyroxine and glucocorticoid [T4+GC] treatment with mini-osmotic pumps, whereas the intact rats 
underwent sham operation. At day zero, the onset of GH treatment (mini-osmotic pumps implantation) was performed in the 
GH animals, whereas both intact and Hx animals underwent sham operation. * indicate p<0.05 between pre- and post-GH 
treatment in GH group.
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(Hx:291 ± 4 to 290 ± 6 beat/min, Intact: 351 ± 7 to 368 ±
7 beat/min). At day 14, the HR, but not MAP, was signifi-
cantly changed between the groups (p < 0.05 Hx vs GH, p
< 0.05 GH vs Intact and p < 0.05 Hx vs Intact).
Growth hormone decreasing effect on blood pressure was 
NO dependent, Fig 3 and 4
Early L-NAME treatment
Both intact and Hx rats had a similar BP response to L-
NAME with an increase of approx 45% (Hx from 82 ± 4 to
120 ± 7 mmHg, Intact from 99 ± 6 to 142 ± 8 mmHg, Fig
3). Growth hormone treatment caused a significantly
greater BP response of approx 56% (GH from 71 ± 4 to
110 ± 6 mmHg, p < 0.05 vs. Intactand Hx, Fig 3).
Late L-NAME treatment
There was no difference in the response of MAP to L-
NAME between the groups (Intact from 91 ± 6 to 144 ± 9
mmHg, Hx from 76 ± 5 to 126 ± 5 mmHg, GH from 74 ±
4 to 120 ± 9 mmHg, Fig 4).
Aortic eNOS expression was unaffected after 14 days of 
GH substitution
Hypophysectomy per se, had no effect on aortic eNOS
protein levels (Intact: 121 ± 31 vs Hx:91 ± 26%). There
was no significant change in aortic eNOS expression after
GH treatment compared with both Hx and Intact rats
(GH: 110 ± 16 %).
Growth hormone effects on basal urine and plasma nitrate 
and nitrate clearance
The urine nitrate was lower, but not significantly
decreased in the Hx group compared to GH and intact
(Hx: 216.16 ± 72.23, Intact: 400.15 ± 94.65, GH: 641.1 ±
208.7 µM/ml/100 g BW n.s.). Both Hx and GH rats had
significantly higher levels of plasma nitrate compared
with intact rats (Hx: 79.4 ± 5.9, GH: 78.2 ± 5.7, Intact:
46.4 ± 2.3 µM, p < 0.05 between Hx and intact and
between GH and intact). The nitrate clearance was calcu-
lated in all groups, demonstrating that GH had an
increased clearance compared with Hx rats, but similar
Effect of a single dos of L-NAME (15 mg/kg, s.c.) on mean arterial blood pressure (MAP) in hypophysectomized (Hx, solid line),  growth hormone supplemented Hx (GH, solid squares) and in intact rats (solid triangles). Figure 3
Effect of a single dos of L-NAME (15 mg/kg, s.c.) on mean arterial blood pressure (MAP) in hypophysectomized (Hx, solid line), 
growth hormone supplemented Hx (GH, solid squares) and in intact rats (solid triangles). The L NAME injection was given 
early, at day three or four (see in method section for further information) after onset of GH treatment. *indicates p<0.05 
between GH and intact or Hx animals.
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with intact rats (Hx:1.8 ± 0.6, GH: 6.2 ± 2.0, Intact: 6.2 ±
1.5 µl/min/100 g, p < 0.05 between Hx and intact and
between GH and intact).
Growth hormone caused a blunted baroreceptor activity, 
Fig 5
The baroreceptor activity, tested by phenylephrine, was
similar in intact and Hx rats (Intact: -0.94 ± 2.29, Hx: -
2.35 ± 0.69 bpm/mmHg, Fig 5). In contrast, GH resulted
in a blunted baroreceptor activity (0.12 ± 0.82, p < 0.05 vs
Hx, Fig 5). When the rats were pre-treated with L-NAME,
none of the groups differed in baroreceptor activity
(Intact: -2.41 ± 2.4, Hx:-2.23 ± 0.68, GH: -0.51 ± 0.40
bpm/mmHg).
Growth hormone increases body weight
The BW of the Hx group did not change over time, indi-
cating a complete hypophysectomy (from arrival to the
onset of treatment: Intact: 295 ± 11 to 391 ± 24 g, Hx: 251
± 19 to 225 ± 13 g, GH: 256 ± 14 to 232 ± 15 g, p < 0.05
between Intact and Hx, Intact and GH at both time
points). After 14 days of treatment, the [T4+GC] group did
not change in BW compared to pre-treated weight (Hx:
232 ± 8 to 232 ± 7 g). The Intact group increased by
approx. 2% in BW during this period (391 ± 24 to 399 ±
28 g, N.S.). The GH group increased in BW by 5% during
the treatment period (from 256 ± 14 to 268 ± 19 g, p <
0.05).
Growth hormone caused a increased plasma IGF-I
Plasma IGF-I decreased in Hx rats by approx. 85% com-
pared with Intact rats (Intact:1098 ± 46 vs Hx 164 ± 27 ng/
ml, p < 0.05). There was a substantial increase in plasma
IGF-I after 14 days of GH therapy by approx. 8-fold
increase (Hx: 164 ± 27 vs GH: 736 ± 56 ng/ml, p < 0.05).
Growth hormone treated rats displayed a significant
decrease in plasma IGF-I compared with intact rats (p <
0.05).
Effect of a single dos of L-NAME (15 mg/kg, s.c.) on mean arterial blood pressure (MAP) in hypophysectomized (Hx, solid line),  growth hormone supplemented Hx (GH, solid squares) and in intact rats (solid triangles). Figure 4
Effect of a single dos of L-NAME (15 mg/kg, s.c.) on mean arterial blood pressure (MAP) in hypophysectomized (Hx, solid line), 
growth hormone supplemented Hx (GH, solid squares) and in intact rats (solid triangles). The L NAME injection was given late, 
at day eleven to twelve (see in method section for further information) after onset of GH treatment.
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Growth hormone effect on heart weight and structural 
parameters of the resistance vessels, Table 1 and Fig 6
The relative LV weight was not changed between Hx and
intact animals. Surprisingly, there was a significant loss of
weight in the LV after GH therapy by approx. 2% (p < 0.05
vs Hx rats, Table 1). The RV weight was not changed
between the groups (Table 1).
The skeletal muscle vascular bed in Hx rats showed an
increased sensitivity (left shift) to administered NA by
approx. 22% compared with intact rats (Table 1), indicat-
ing an increased sensitivity of the vascular á-adrenocep-
tors. Treatment with GH resulted in a normalisation of the
NA sensitivity (right shift) (Table 1). The perfusion resist-
ance (PR) obtained at maximal dilation was decreased by
approx. 19% in both GH and Hx group compared with
intact rats (Intact: 1.94 ± 0.06, Hx: 1.16 ± 0.04, GH: 1.12
± 0.08 mmHg/ml/min/100 g dry HQ, p < 0.05 vs intact
and GH and Hx, Fig 6A). When vasoconstriction was
induced by means of NA or with angiotensin II+phenyle-
phrine, both Hx and GH group showed approx. 42% and
40%, respectively, decreased resistance response com-
pared with intact rats (Table 1). Similar resistance changes
were obtained in GH, Hx and intact rats after maximal
constriction was induced by BaCl2 (Intact: 61 ± 7, Hx: 26
± 5, GH: 31 ± 4 mmHg/ml/min/100g dry HQ, p < 0.05
Intact vs GH and Hx, Fig 6B). The average slope calculated
from individual pressure-flow curves, also obtained dur-
ing full vascular relaxation, showed similar magnitude of
structural changes between Hx, GH and intact rats (Intact:
0.84 ± 0.04, Hx: 0.47 ± 0.02, GH: 0.44 ± 0.03 mmHg/ml/
min/100 g dry HQ, p < 0.05 Intact vs GH and Hx, Fig 6C).
Both the GH treated and Hx rats showed endothelial dys-
function compared with Intact rats, demonstrated by
decreased dilation after a single dose of acetylcholine
(Intact: 73 ± 1%, Hx: 65 ± 3%, GH: 61 ± 4%, Fig 6D).
Discussion
The major findings in this study are; (i) Hypophysectomy
per se, caused a decrease in MAP and HR, endothelial dys-
Baroreceptor activity was tested in hypophysectomized (Hx, open squares), growth hormone treated Hx rats (GH, solid  squares) and in intact rats (solid triangles) Figure 5
Baroreceptor activity was tested in hypophysectomized (Hx, open squares), growth hormone treated Hx rats (GH, solid 
squares) and in intact rats (solid triangles). Baroreceptor activity test was performed with a single dose of phenylephrine (4 mg/
kg, s.c.). Mean arterial blood pressure (MAP) and heart rate (HR) were correlated to each other and the k-values were calcu-
lated in all groups. *indicate a significant difference of the slope between Hx and GH rats.
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function and reduced vasculature mass in the hindquarter
vascular bed. (ii) Supplementation with [T4+GC] did not
change any of the studied parameters. (iii) GH substitu-
tion resulted in a transient decrease in MAP and a tran-
sient increase in HR. (iv) GH substituted rats had an
increased MAP response after administration of early L-
NAME compared with intact and Hx rats, indicating a
transient activation of NO by GH. (v) Long-term GH treat-
ment resulted in an impaired baroreceptor activity. (vi) 14
days of GH therapy to Hx rats neither improved the
endothelial function nor restored the vascular structure.
Taken together, GH substitution seems to have a short
lasting effect on lowering blood pressure via activation of
the NO-system. The transient increase in HR is most likely
mediated by a baroreceptor activation. These data also
suggest that a longer period of GH therapy is required to
improve endothelial function and to restore the morphol-
ogy of the vasculature. Finally, there is interplay between
GH, NO-system and blood pressure regulation.
The effect of GH on blood pressure
Growth hormone therapy to Hx rats caused an immediate
and transient decrease in MAP. This reduction in MAP
appears to be NO-dependent since L-NAME treatment
caused a greater MAP response than it did in both Hx and
intact rats. We speculate that this finding may reflect an
increase in eNOS activity and/or expression, resulting in
enhanced NO bioavailability. This may in turn lead to
decreased total peripheral resistance [6,14], resulting in
reduced MAP. Growth hormone and IGF-I has been
shown to increase eNOS in vitro [15] as well as to increase
eNOS expression [12] and NO formation [2]in vivo.
It has been suggested that GH treatment can be associated
with an increase in extra cellular volume (ECV) [16-18].
An increased volume load may theoretically lead to an
increase in BP. However, a previous published study
showed that increased body sodium concentration and
increased ECV after GH substitution to GHD patients
were not associated with an increase in BP [18]. Taken
together, this suggests that the load of ECV seems to be of
minor importance for the BP regulation at least in GH
treated GHD patients.
The GH activated NO-dependent decrease in MAP appears
to be transient since 12 days of GH therapy, results in a
similar increase in MAP after a single dose of L-NAME as
it did in both intact and Hx animals. This result is sup-
ported by unchanged aortic eNOS expression in all groups
and the return of MAP to pre-treatment levels in GH
treated rats. The present study showed increases of urine
nitrate after 12 days of GH treatment, which may suggest
that there is still some GH stimulated NO production left,
although this increase appears to be of minor importance
for the BP regulation. The level of MAP in GH rats did not
return to the level in intact rats. It is possible that the
observed reduction of the resistance vessels mass in the
hindquarters vascular bed could be the explanation.
Folkow et al [13] have shown that 6 weeks of treatment
with both GH and T4 results in normalisation of BP as well
Table 1: Effects of 14 days of administration of thyroxine (T4), glucocorticoids (GC) and growth hormone (GH) were studied in male 
hypophysectomized (Hx) rats. Intact rats were also used. The parameters that were studied were: body weight (BW), wet hindquarter 
(HQ weight), dry HQ, oedema, left (LV) and right (RV) ventricular and heart weight (HW) as well on structural properties in the 
skeletal muscle bed. The perfusion resistance (PR) was calculated as PR/flow (ml/min)/100g dry HQ weight for noradrenalin and 
angiotensin II (Ang II)/phenylephrine (Phe) responses. The ED-50 value demonstrates the half-maximal effect of the effective 
noradrenalin dose, demonstrating the adreno-receptor sensitivity. Maximal noradrenaline and Ang and Phe responses reflect the 
average medial bulk of contractile tissues. Values are expressed as MEAN±SE. §denotes that both protocol 1 and 2 are included. 
*denotes that the number in the groups are changed, intact group n=8, Hx-group n=6 and GH group n=6. adenotes p<0.05 vs. intact, 
bdenotes p<0.05 vs. Hx-[T4+GC].
Intact Hx [T4+GC] Hx GH+ [T4+GC]
N 14 12 12
BW (g) 402 ± 5 222 ± 3a 265 ± 5a, b
Wet HQ weight (g/100 g BW) 44.4 ± 1.0 43.3 ± 3.1 41.7 ± 1.7a
Dry HQ weight (g/100 g BW) 21.6 ± 0.3 18.4 ± 0.6a 15.6 ± 1.7a, b
Oedema (%) 51 ± 1 57 ± 2 62 ± 2a, b
LV weight (mg/100 g BW)§ 161.6 ± 12.6 164.4 ± 16.2 158.5 ± 14.7b
RV weight (mg/100 g BW)§ 41.9 ± 9.9 42.1 ± 9.8 39.9 ± 9.9
HW (mg/100 g BW)§ 203.3 ± 15.0 206.5 ± 20.3 186.4 ± 29.3a, b
ED 50 value of noradrenalin 0.593 ± 0.066 0.463 ± 0.05a 0.584 ± 0.074b
PR Noradrenalin response 
(mmHg/ml/min/100 g dry HQ)
23.64 ± 2.4 13.8 ± 0.8a 13.8 ± 1.4a
PR Ang II + Phe response 
(mmHg/ml/min/100 g dry 
HQ)*
33 ± 7 17 ± 2 22 ± 5
Values are expressed as MEAN ± SE. §denotes that animals from both protocol 1 and 2 are included. *denotes that the number in the groups are 
changed, intact group n = 8, Hx-group n = 6 and GH group n = 6. adenotes p < 0.05 vs. intact, bdenotes p < 0.05 vs. Hx- [T4+GC]BMC Physiology 2005, 5:17 http://www.biomedcentral.com/1472-6793/5/17
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Graphs A-C showing the effect of hypophysectomy (Hx) and 14 days of growth hormone substitution to Hx rats (GH) on  structural properties and acetylcholine response (D) in the skeletal vascular bed Figure 6
Graphs A-C showing the effect of hypophysectomy (Hx) and 14 days of growth hormone substitution to Hx rats (GH) on 
structural properties and acetylcholine response (D) in the skeletal vascular bed. (A) Graphs showing the perfusion resistance 
(PR) at maximal dilation (max dil), reflecting the average internal radius of the skeletal vasculature. (B) Graph showing the PR 
at maximal constriction (max con) obtained by barium chloride, reflecting average medial bulk of contractile tissue. (C) Graph 
showing slope, calculated by linear regression from individual pressure-flow curves during perfusion at maximal dilation. (D) 
Linear graph showing the resistance pre (during maximal noradrenaline constriction) and post (after a single dose of acetylcho-
line) in the skeletal vascular bed, reflecting the endothelial function. *indicate p < 0.05 between intact and GH or Hx rats.
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as an enhanced vascular mass in the hindquarter vascular
bed. In GH over-expressed mice, increased vascular mass
has also been described [19,20]. These mice displayed
either hypertension [19] or normotension [20]. Thus, it
seems that a longer supplementation period is required to
give an effect of vascular morphology on the resistance
vessels as well as to normalise BP. However, hGH treat-
ment to Hx rats for longer periods than two to three weeks
have been reported to result in antibodies against GH
[21]. Guided by this information, we decided to limit the
study to two weeks.
Growth hormone effect on heart rate and the 
baroreceptor activity
In the present study, GH substitution results in an imme-
diate and transient increase in HR, which is partly in
accordance with other studies [2,6]. This direct effect in
HR can probably be explained by an increased sympa-
thetic activity that could originate from increased firing of
baroreceptors in response to decreased MAP. Two weeks
of GH therapy resulted in a normalisation of HR. This
transient change in HR might be explained by deactiva-
tion of baroreceptors due to increased BP. After twelve
days of GH therapy, baroreceptor activity was blunted.
The blunted effect of the baroreceptors can most likely be
explained in two ways; by loss of structure or by "reset-
ting". Both GH and Hx rats showed reduced vasculature
mass in the hindquarter vascular bed, but only GH treated
rats exhibit impaired function of the baroreceptors, sug-
gesting that the blunted function of the baroreceptors
could not be due to loss of structure in the baroreceptors
in GH rats. Therefore, our data suggest that the impaired
function of the baroreceptors seems to be related to "reset-
ting". It has been suggested that NO appears to act as a
sympatholytic agent to modulate the central sympathetic
outflow [22]. The impaired baroreceptor activity appears
not to be NO-dependent, since the blunted effect of the
baroreceptors was unchanged after L-NAME treatment.
Growth hormone effect on adreno-receptor sensitivity and 
endothelial function
Growth hormone treated Hx rats showed a right shift and/
or normalisation of the noradrenalin ED50 value in the
hindquarters vascular bed, which is in accordance with
other studies [11,13,19]. Long-term GH replacement in
GHD patients has been shown to decrease sympathetic
activity to the muscular vascular bed [23], whereas heart
rate variability displays increased ratio of sympato-vagal
tone, decreased vagal tone and increased sympathetic
tone [24]. This might suggest that the rightward shift and/
or normalisation of the noradrenalin ED50 value in the
hindquarter vascular bed is caused by increased sympa-
thetic tone and changed ratio between the sympato-vagal
and the vagal tone.
It is well known that GHD patients exhibit endothelial
dysfunction [1,25]. This phenomenon has been detected
in both conduit [11] and resistance vessels in Hx rats [10].
Accordingly, in this study the resistance vessels in the
hindquarter vascular bed also exhibit endothelial dys-
function in Hx rats. Neither one week [10] nor two weeks
of GH therapy resulted in improved endothelial function
in the resistance vessels. In contrast, both GH supple-
mented GHD patients [7] as well as GH treated Hx rats
[11] show improved endothelial function in the conduit
vessels. This suggests that longer treatment is required to
enhance the endothelial function in the resistance vessels.
Conclusion
Hypophysectomy  per se, is associated with decreased
MAP, HR and loss of vascular structure. Growth hormone
substitution to Hx rats results in a transient decrease in
MAP and a transient increase in HR. This transient
decrease of MAP was NO dependent. Growth hormone
treatment caused an impaired baroreceptor activity. Two
weeks of GH therapy neither improved the endothelial
function nor restored vascular parameters. To summarize,
GH substitution seems to have a short lasting effect on
lowering blood pressure via activation of the NO-system.
These data also suggest that a longer period of GH therapy
is required to improve endothelial function and to restore
the morphology of the vasculature. Finally, there is an
interplay between GH, blood pressure and NO-system.
Methods
Animals
Male Wistar rats were obtained from M&B (Ejby, Den-
mark). The rats underwent hypophysectomy at approxi-
mately eight weeks of age (approx. 280–300 g) at M&B
one week prior arrival to our facility. The protocol con-
formed to guidelines on the conduct of animal experi-
ments issued by the Swedish National Board for
Laboratory Animals and was approved by the Ethics Com-
mittee for Animal Experiments at Göteborg University.
The animals were housed at constant temperature (20°C)
at a relative humidity of 50–60%. A 12 h dark/light cycle
was maintained with lights on/off at 07.00 AM to 7.00
PM. The rats had free access to standard pellet chow and
tap water throughout the study. All rats were acclimatized
for one week before the onset of the experiment. Body
weight (BW) was measured throughout the study once a
week.
Experimental protocol
Two different experimental protocols were used.
Substitution therapy
In both protocol 1 and 2 (see below), all Hx rats received
thyroxine (T4, 20 µg/kg/day) and glucocorticoid (GC, 400
µg/kg/day) ([T4+GC]) treatment by mini-osmotic pumpsBMC Physiology 2005, 5:17 http://www.biomedcentral.com/1472-6793/5/17
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s.c. (model 2004, Alza Pharmaceuticals, Palo Alto, CA,
USA). After two days of [T4+GC] treatment, the Hx rats
were divided into two groups of which one was treated
with GH (1 mg/kg/day) by a second mini-osmotic pump
s.c. (2ML2) for 14 days.
Protocol 1
Hypophysectomized rats and intact controls were
equipped with telemetry transmitters for measurement of
conscious unrestrained MAP and HR for 18 days (Intact n
= 5, Hx n = 8, and GH n = 5). MAP and HR were measured
two days before onset of treatment (Day -4 to -2) and con-
tinued throughout the start of substitution with [T4+GC]
(Day -1 to 0) and treatment with GH (Day 1–14). In addi-
tion to these baseline measurements, two different exper-
iments were performed; 1) the activity of the NO system
was assessed by acute administration of L-NAME (early,
Day 3–4) and (late, Day 11–12), 2) baroreceptor activity
was assessed by acute administration of phenylephrine
(Day 11–12). Two days of baseline measurements were
recorded before onset of these two experiments. At the
end of the 14 day protocol, rats were anesthetized, sacri-
ficed and blood and tissues samples were taken for further
analyses.
Protocol 2
Rats in the second protocol were treated identically as in
protocol 1, except that we did not implant telemetry trans-
mitters (Intact n = 14, Hx n = 12, and GH n = 12). In this
protocol, two different experiments were performed; 1)
plasma and urine nitrate concentrations were measured
(Day 10–12), 2) at the end of the 14 day protocol, vascu-
lar structure as well as endothelial function in the hind-
quarter vascular bed was assessed using an in vivo con-
stant-flow preparation.
Experimental procedures
Implantation of radio-telemetric implants
During the high dose substitution therapy (see below), a
radio telemetric transducer catheter (o.d. 0.76 mm, Data
Science International, Inc, St. Paul, MN, USA) was
implanted into the lower aorta and glued into position (3
M Vetbond™, 3 M Animal Care Products, St Paul, MN,
USA) in Hx (n = 13) and control (n = 5) rats. Rats were
anaesthetized using Ketalar:Rompun (39:5 mg/kg) and
isoflurane (Baxter Healthcare, Chicago, MI, USA). The
catheter tip was placed at least 1 cm below the renal arter-
ies. The transmitter (TA11PA-C40) was secured to the
abdominal wall and the abdomen closed with sutures.
After four weeks of recovery and without hormonal sup-
plementation, the animal in its home cage was placed on
a receiver plate and the signal collected using the
Dataquest LabPRO Acquisition System (Ver. 3.0, Data Sci-
ences international, Inc, St. Paul, MN, USA). The follow-
ing sampling parameters were used; sampling frequency
500 Hz, sample duration 15 sec., save period 5 min. The
mean arterial signal was corrected for electronic offset, the
average of one measurement outside the animal before
and after implantation.
High dose substitution therapy to improve surgical survival
To be able to perform surgery on the vulnerable Hx rats,
high-dose steroid therapy and salt (NaCl) enriched diet
was given before and after surgery according to the follow-
ing protocol. For five days all rats (Hx and intact rats) had
free access to normal tap water and dexamethasone in tap
water (orally, 1.5 mg/l). Rats also received standard pellet-
and salt pellet chow (248 mmol/100 g, Lactamin, Vad-
stena, Sweden). The rats were also treated with glucocorti-
coid at day 1: 2 mg/kg × 2, day 2: 2 mg/kg × 3, day 3: (day
of surgery): 2 mg/kg × 4, day 4: 2 mg/kg × 3 and day 5: 2
mg/kg × 2 (s.c.). This high dose regime was washed out
during the following four weeks before onset of the exper-
iment. During this period the rats received no hormonal
treatment, but had free access to salt pellet and standard
pellet chow. Using this regime 75% of Hx animals sur-
vived the surgical procedure.
NO dependency protocol
To test if the NO system was involved in the GH-depend-
ent BP regulation, a NOS antagonist (L-NAME 15 mg/kg,
s.c.) was given during two occasions, early (day 3–4) and
late (day 11–12). Saline was used as a control and given
in an equal volume (0.1 ml/kg, s.c.). L-NAME and saline
were given in randomized order.
Test of baroreceptor activity
The baroreceptor activity was tested by using phenyle-
phrine (300 µg/kg, s.c.) after pre-treatment with NaCl or
L-NAME at day 11–12. Three hours after late L-NAME or
saline were given; all rats received a single dose of phe-
nylephrine to generate a slow gradual increase in MAP
and a corresponding baroreceptor elicited decrease in HR
within 60 seconds. L-NAME and NaCl were given in ran-
domized order. To determine the optimal dose of phe-
nylephrine, a dose response curve was established in
separate experiments (data not shown).
End of experiment
On day 13–14 the rats were allowed to recover and base-
line measurements were performed. At day 14, the rats
were anesthetized using isoflurane and decapitated. Blood
samples were taken for IGF-I analysis. The heart and the
aorta were quickly excised. The heart was separated into
left (LV) (including septum), and right ventricles (RV) and
weighed. The aorta was trimmed free of fat and adherent
tissues, frozen in liquid nitrogen and stored at -80°C for
further analysis.BMC Physiology 2005, 5:17 http://www.biomedcentral.com/1472-6793/5/17
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Measurements of IGF-I
In randomly selected plasma samples from protocol 1, the
plasma IGF-I content was analyzed by a commercial RIA
kit (Mediagnost, Reutlingen, Germany) in intact rats (n =
3), Hx rats (n = 5) and in GH (n = 5) treated rats [12].
Immunoblotting
Immunoblotting and protein extraction techniques have
previously been described [12]. Briefly, protein was
extracted from the aorta from intact rats (n = 5), Hx rats (n
= 8) and GH (n = 5) treated Hx rats. The total protein con-
centration was determined by a commercial protein assay
(Bio-Rad, Hercules, CA, USA). 25 µg of aorta and liver of
total proteins were loaded in each lane on gels (10%
NuPAGE® Bis-Tris gels; Novex, San Diego, CA, USA). The
gels were run for 90 minutes at constant voltage (150 V).
Molecular weight standards (See Blue®; Novex, San Diego,
CA, USA) were used on each gel. The proteins were trans-
ferred to a polyvinyldifluoride (PVDF) membrane (Amer-
sham, Buckinghamshire, UK). The membranes were
incubated with a mouse monoclonal antibody against
eNOS (dilution 1:1,000; Transduction Laboratories, Lex-
ington, KY, USA). Immunoreactive protein was visualized
by chemiluminescence using an alkaline phosphatase-
conjugated secondary antibody (dilution 1:30,000;
Sigma, St. Louis, MO, USA) and CDP-Star® (Tropix, Bred-
ford, MA, USA) as a substrate. The membranes were
exposed to ECL film (Amersham, Buckinghamshire, UK)
at room temperature for 1–5 minutes and the films were
subsequently developed. Semi quantitative measure-
ments of proteins from the immunoblots were made by
densitometry (Fluor-S™ Multimager, Quantity One ver.
4.1.0, Bio-Rad, Hercules, CA, USA). The optical density
(OD) of each band was measured. Lane containing extract
of liver was used as a reference on each gel.
Nitrate measurements
The animals were housed individually in metabolic cages.
During the first day of measurement, the rats had free
access to tap water and standard pellet chow. During the
second and the third day in the metabolic cages, fasting
was induced in the animals over night with free access to
distillate water. This was in order to avoid interference of
food and water on the nitrate measurement [26]. Water
intake, urine volume and BW were measured. During the
last day of measurements, the urine was collected for 24
hours, weighed and frozen for further nitrate analysis. At
the end of the protocol, a blood sample of approximately
200 µl was drawn from the tail vein. The whole blood was
centrifuged and plasma was collected and frozen for fur-
ther analysis.
Plasma and urine nitrate analyses
Plasma and urine samples were analyzed for total nitrate
concentration using a gas chromatography/mass spectro-
metric method as previously described [27]. Briefly, after
the samples had been prepared, the samples were injected
into a Varian 3400 gas chromatograph equipped with a 30
m BPX-5 capillary column operated with a temperature
program (60–240°C). A Varian Saturn II mass spectrom-
eter served as detector operating in the positive ion/chem-
ical ionization mode using methane as the reactant gas
and selective monitoring of mass equivalent m/z 124 for
endogenous nitrate and mass equivalent m/z 125 for the
15N-labelled internal standard. Basal urine and plasma
nitrate concentrations and nitrate clearance were calcu-
lated.
Hemodynamic analysis of resistance-vessel design
The structural characteristics of the skeletal muscle vascu-
lature were analysed hemodynamically using a method
which has been described in detail previously [13]. In
brief, the isolated hind limbs of randomly treated and
untreated rats were perfused in pairs via an aortic cannula.
The perfusate consisted of an oxygenated 2% dextran-
Tyrode solution, to which 0.5% bovine serum albumin
(Sigma Chemicals, St Louis, MISS, USA) had been added.
Perfusion pressure was measured via the cannulated tail
artery. The hind limb vascular bed was initially maximally
dilated by repeated injections of papaverine (3 mg
totally), using constant flow of 10 ml/100 g hind limbs.
Pressure-flow curves during maximal dilatation were con-
structed by altering the speed of the perfusion pump. Dur-
ing this constant flow condition, noradrenalin (NA) in
increasing concentrations was added to the perfusate (20–
64 µg). At maximal NA constriction, an injection of acetyl-
choline (0.01 mg, the correct dose was tested out by dose
response curves, data not shown) was given. Finally, angi-
otensin II (200 ng), phenylephrine (4 mg) and BaCl2 (150
mg) were injected. Noradrenalin dose-resistance curves
were constructed of hind limb vascular beds, and the ED50
value was calculated. After the experiment, the hindquar-
ters were dried at 70°C for 48 h and weighed. The dry
weight of the HQ was used to standardize the calculation
of the hemodynamic parameters.
Hormones, solutions and drugs
The following hormones were used; Thyroxine (T4, L-thy-
roxine; Nycomed, Oslo, Norway); Glucocorticoid (GC,
cortisol phosphate; Solu-Cortef, Upjohn, Puurs, Bel-
gium); human Growth hormone (hGH, Pharmacia,
Stockholm, Sweden). Thyroxine, glucocorticoids and
hGH were dissolved in 0.9% NaCl.
The composition (in mM) of the 2% dextran Tyrode solu-
tion used in the infusion experiments was Na+ 148.0, Cl-
133.4, K+ 4.3, Ca2+ 2.5, Mg2+ 0.8, HCO3 25, H2PO4 0.5, D-
glucose 5.6.BMC Physiology 2005, 5:17 http://www.biomedcentral.com/1472-6793/5/17
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The following drugs were used: acetylcholine (Sigma);
Angiotensin II (Sigma); Phenylephrine (Sigma);
Noradrenalin (Sigma); Nω-nitro-L-arginine methyl ester
(L-NAME, Sigma); Dexamethasone (Sigma); Papaverine
(Sigma).
Statistical analysis
Values are expressed as MEAN ± SE. Statistical analyses of
BW, plasma IGF-I, eNOS expression, basal urine and
plasma nitrate and nitrate clearance, all HQ-data, BP and
HR comparisons between the groups and percentages
changes after L-NAME treatment were performed by one-
way ANOVA followed by Tukey's as a post-hoc test. Hor-
monal effects on the BP and the HR was calculated by
using paired t-test of mean of 24 h before onset of treat-
ment compared to mean of 24 h after onset of treatment.
L-NAME percentage effect on BP was calculated by com-
paring 10 values pre-treatment and 10 values post-treat-
ment. Individual k-values was calculated when
barorecteptor activity was studied.
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